Welcome to our dedicated page for Cullinan Oncology SEC filings (Ticker: CGEM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cullinan Therapeutics, Inc. (Nasdaq: CGEM) SEC filings page on Stock Titan provides access to the company’s public disclosures filed with the U.S. Securities and Exchange Commission. These documents include Current Reports on Form 8-K, which Cullinan uses to report material events such as clinical data updates, financial results, regulatory milestones, and significant corporate actions related to its biopharmaceutical business.
For a clinical-stage company like Cullinan, SEC filings are a primary source of detail on the development of its T cell engager and targeted therapy programs. Recent 8-K filings describe updated Phase 1 data for CLN-049, an FLT3xCD3 bispecific T cell engager in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome, including response rates, safety findings, and the impact of FDA Fast Track designation. Other filings summarize financial results, cash and investment levels, and expectations for cash runway under the company’s operating plan.
Filings may also reference Cullinan’s work in autoimmune diseases with CLN-978, a CD19xCD3 bispecific T cell engager, and its collaboration with Taiho Oncology and Taiho Pharmaceutical on zipalertinib (CLN-081/TAS6417), an EGFR inhibitor for non-small cell lung cancer. These reports can include information on clinical timelines, regulatory interactions, and program prioritization decisions, such as the discontinuation of certain assets or the termination of license agreements.
On Stock Titan, investors can review Cullinan’s SEC filings alongside AI-powered summaries that highlight key points from lengthy documents, helping to interpret complex clinical and regulatory language. Users can monitor new 8-K submissions in real time and place them in context with the company’s broader pipeline and news flow, supporting deeper analysis of CGEM’s risk profile, development progress, and strategic direction.
Cullinan Therapeutics Inc ownership update: The Vanguard Group reports beneficial ownership of 0 shares of Common Stock as of the amendment filing, following an internal realignment. The filing states on January 12, 2026 certain Vanguard subsidiaries will report ownership separately in reliance on SEC Release No. 34-39538.
Cullinan Therapeutics, Inc. files its annual report describing an expanded pipeline in autoimmune disease and oncology and its collaboration strategy. The company highlights CLN-978, a CD19xCD3 T cell engager in Phase 1 trials for lupus, rheumatoid arthritis and Sjögren’s disease, and velinotamig, a BCMAxCD3 engager licensed from Genrix for plasma cell–driven autoimmune conditions.
In oncology, CLN-049, a FLT3xCD3 T cell engager for AML and MDS, has Phase 1 data showing complete response plus partial hematologic recovery rates up to 31% at certain doses and has Fast Track designation. Zipalertinib, partnered with Taiho, has pivotal REZILIENT1 data in EGFR exon 20 insertion NSCLC, supporting a completed rolling NDA submission for accelerated approval and a global Phase 3 first-line trial now fully enrolled. The company also outlines substantial potential milestone and profit‑share economics from Taiho and details key licensing agreements and an IP estate with patents extending into the 2040s.
Cullinan Therapeutics reported a full-year 2025 net loss attributable to the company of $219.9 million, compared with $167.4 million in 2024, driven mainly by higher research and development spending. Cash, equivalents, investments and interest receivable totaled $439.0 million as of December 31, 2025, which the company expects will fund operations into 2029.
The company highlighted multiple 2026 milestones, including initial clinical data for CLN-978 in systemic lupus erythematosus and rheumatoid arthritis in Q2 2026 and repeat dosing data in Q3 2026. Partner Taiho completed a rolling NDA submission and enrollment of the REZILIENT3 frontline study for zipalertinib, while Cullinan plans to advance CLN-049 toward registrational development in acute myeloid leukemia.
Cullinan Therapeutics, Inc. Chief Scientific Officer Jennifer Michaelson reported option exercises and a share sale. On the same day, she exercised stock options for 4,000 shares of common stock at $4.30 per share through a derivative exercise, and then sold 8,000 common shares in the open market at a weighted average price of $15.68 per share, with individual trades ranging from $15.38 to $16.31. The sale was made under a pre-established Rule 10b5-1 trading plan dated August 7, 2025. Following these transactions, she directly held 170,844 shares of common stock and 120,987 shares underlying stock options.
Jennifer Michaelson reported Form 144 proposed sales of Common shares. The filing lists an exercise of stock options for 4,000 shares dated 03/05/2026 and 4,000 Restricted Stock Units dated 12/11/2024.
The excerpt also itemizes multiple 10b5-1 sale transactions by Ms. Michaelson during late 2025 and early 2026, including 8,000 shares on 02/20/2026, 4,000 shares on 01/22/2026, and smaller lots on various dates with dollar amounts shown.
Cullinan Therapeutics ownership disclosure by Kynam Capital group. The filing reports that Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang beneficially own 3,114,132 shares of Cullinan Therapeutics common stock, equal to 5.27% of the class as of 12/31/2025.
The disclosure lists shared voting and dispositive power of 3,114,132 shares and zero sole voting or dispositive power. The report includes the issuer CUSIP 230031106 and the filer address in Princeton, New Jersey.
Cullinan Therapeutics Chief Scientific Officer Jennifer Michaelson reported an open-market sale of 1,780 shares of common stock at a weighted average price of $14.14 per share. After this transaction, she directly holds 174,844 shares of Cullinan Therapeutics common stock.
The sale was effected under a pre-arranged trading plan established pursuant to Rule 10b5-1 on August 7, 2025. The reported price reflects a weighted average for multiple trades executed between $13.89 and $14.35 per share.
Cullinan Therapeutics, Inc. Chief Scientific Officer Jennifer Michaelson reported selling a total of 5,353 shares of common stock in open-market transactions. She sold 3,601 shares on February 24, 2026 at a weighted average price of $14.47 per share and 1,752 shares on February 23, 2026 at a weighted average price of $13.99 per share. These sales were effected under a Rule 10b5-1 trading plan and were described as covering personal income tax obligations upon vesting of restricted stock units. After the transactions, she directly holds 176,624 Cullinan Therapeutics common shares.
Cullinan Therapeutics reported that President and CEO Nadim Ahmed executed an open-market sale of 13,515 shares of common stock at $14.47 per share. According to the filing, the sale was made to cover personal income tax obligations upon vesting of restricted stock units. After this transaction, he directly owned 390,803 shares.
Cullinan Therapeutics Chief Medical Officer Jeffrey Alan Jones reported an open-market sale of 4,582 shares of common stock at $14.47 per share. According to the footnote, the sale was made to cover personal income tax obligations upon vesting of restricted stock units. After this transaction, Jones directly holds 159,968 shares of Cullinan Therapeutics common stock.